What are the current common specifications of generic versions of giritinib?
Gilteritinib is a targeted drug used to treat acute myeloid leukemia (AML). It is currently on the market in China, but has not yet been included in the medical insurance system. This makes it difficult for patients to purchase giritinib in domestic hospitals, especially because the supply in pharmacies in some areas is insufficient. Therefore, many patients choose to purchase through overseas channels to meet their treatment needs.
In foreign markets, giritinib has both original drug and generic drug options. The original drugs mainly include the European version and the Hong Kong version, and the specifications are mostly 40mg and 80mg tablets. The price of the Hong Kong version of giritinib is very high. The price of a box of the drug can be as high as about 100,000 yuan, which brings a large financial burden to patients. Despite this, original drugs are still preferred by some patients because of their brand name and quality assurance.

In contrast, generic versions of gilitinib offer a more affordable option. Taking the Laos version as an example, its common specifications are similar to the original drug, mainly including 40mg and 80mg tablets, with prices ranging from one thousand to more than two thousand yuan. This lower price greatly reduces the financial pressure on patients. At the same time, the ingredients of generic drugs are basically the same as those of the original drugs, ensuring the effectiveness and safety of the treatment.
Generally speaking, the generic version of giritinib is consistent with the original drug in terms of specifications and has obvious advantages in price. For patients who need to take the drug long-term, choosing a generic version is an economical and feasible option. When purchasing drugs, patients should ensure that they go through formal channels, follow the doctor's instructions, and choose the most appropriate drug specifications based on their own circumstances.
Reference materials:https://www.xospata.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)